Vivek Subbiah

Cancer Prevention Institute of California

Also affiliated with Sarah Cannon Research Institute, Sarah Cannon, Stanford Cancer Institute

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 3%percentile

0.935Author DataRank

Indexed papers

9in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 9 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

The Landscape of Alterations from 1407 Ultra-Rare Sarcomas from the AACR GENIE Database: Clinical Implications

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0876

Top 35%

0.561DataRank

Top 35%8 citations

Justin T. Moyers, Mohamed A. Gouda, Anthony P. Conley, Alexander J. Lazar, Vivek Subbiah +1 more

Papers

Driven by 127 papers — median percentile 0. Top paper: “Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial”.

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

The Lancet Oncology(2020)10.1016/s1470-2045(20)30321-1

N/A

5.7DataRank · unranked

527 citations

Ulrik Lassen, Élena Elez, Antoîne Italiano, Giuseppe Curigliano, Milind Javle +14 more

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

The Lancet Diabetes & Endocrinology(2021)10.1016/s2213-8587(21)00120-0

N/A

5.1DataRank · unranked

354 citations

Mimi I. Hu, Lori J. Wirth, Martin Schüler, Aaron S. Mansfield, Giuseppe Curigliano +20 more

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

The Lancet Oncology(2021)10.1016/s1470-2045(21)00247-3

N/A

5.0DataRank · unranked

445 citations

Giuseppe Curigliano, Dong‐Wan Kim, Ki Hyeong Lee, Benjamin Besse, Christina S. Baik +20 more

Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial

The Lancet Oncology(2022)10.1016/s1470-2045(22)00541-1

N/A

5.0DataRank · unranked

426 citations

Jürgen Wolf, Bhavana Konda, Hyunseok Kang, Alexander I. Spira, Jared Weiss +10 more

Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial

The Lancet Oncology(2021)10.1016/s1470-2045(21)00578-7

N/A

4.9DataRank · unranked

354 citations

Alexander Stein, Martin van den Bent, Jacques De Greve, Antje Wick, Filip Y F L de Vos +21 more

FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies

Annals of Oncology(2022)10.1016/j.annonc.2022.02.001

N/A

4.9DataRank · unranked

200 citations

Nicholas Iannotti, Martin Gutierrez, David C. Smith, Luis Féliz, Christine Lihou +5 more

Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

Nature Medicine(2023)10.1038/s41591-022-02103-8

N/A

4.3DataRank · unranked

388 citations

Naval Daver, Mikhila Mahendra, Jixiang Zhang, Carlos Kamiya-Matsuoka, Funda Meric‐Bernstam +44 more

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

Nature Medicine(2023)10.1038/s41591-023-02321-8

N/A

4.1DataRank · unranked

307 citations

Robert J. Kreitman, Zev A. Wainberg, Anas Gazzah, Ulrik Lassen, Alexander Stein +18 more

Phase 2 study of pembrolizumab in patients with advanced rare cancers

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2019-000347

N/A

4.0DataRank · unranked

131 citations

Funda Meric‐Bernstam, Bettzy Stephen, Daniel D. Karp, Joud Hajjar, Jordi Rodon Ahnert +35 more

Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

Nature Medicine(2022)10.1038/s41591-022-01931-y

N/A

3.9DataRank · unranked

240 citations

Philippe A. Cassier, Salvatore Siena, Elena Garralda, Luis Paz‐Ares, Pilar Garrido +14 more

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0800

N/A

3.5DataRank · unranked

140 citations

Justin F. Gainor, Geoffrey R. Oxnard, Daniel Shao-Weng Tan, Dwight H. Owen, Byoung Chul Cho +16 more

Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors

The Oncologist(2021)10.1002/onco.13682

N/A

1.4DataRank · unranked

47 citations

Henry Hiep Vo, Vivek Subbiah, Filip Jankú, Sarina A. Piha‐Paul, Bülent Yılmaz +7 more

Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-1215

N/A

1.3DataRank · unranked

41 citations

Haeseong Park, S. Greg Call, Kiran Madwani, Yasuhiro Oki, Vivek Subbiah +17 more

Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0974

N/A

1.3DataRank · unranked

44 citations

Sant P. Chawla, Anthony P. Conley, Breelyn A. Wilky, Anthony W. Tolcher, Nehal J. Lakhani +14 more

Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study

Thyroid(2023)10.1089/thy.2023.0363

N/A

1.2DataRank · unranked

55 citations

Mimi I. Hu, Aaron S. Mansfield, Matthew H. Taylor, Martin Schüler, Viola W. Zhu +19 more

The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial

Investigational New Drugs(2021)10.1007/s10637-020-01043-9

N/A

1.1DataRank · unranked

25 citations

Amir A. Jazaeri, Shannon N. Westin, Anil K. Sood, Lois M. Ramondetta, Mingxuan Xu +8 more

Dabrafenib plus trametinib in patients with relapsed/refractoryBRAFV600E mutation–positive hairy cell leukemia

Blood(2022)10.1182/blood.2021013658

N/A

1.1DataRank · unranked

42 citations

Philippe Moreau, Farhad Ravandi, Martin Hutchings, Anas Gazzah, Anne‐Sophie Michallet +12 more

Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies

Cancer Research Communications(2023)10.1158/2767-9764.crc-22-0260

N/A

0.943DataRank · unranked

37 citations

Niamh Coleman, Sarina A. Piha‐Paul, Apostolia M. Tsimberidou, Filip Jankú, Jordi Rodón +13 more

Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology

npj Precision Oncology(2022)10.1038/s41698-022-00317-0

N/A

0.607DataRank · unranked

17 citations

Siqing Fu, David S. Hong, Daniel D. Karp, Sarina A. Piha‐Paul, Vivek Subbiah +18 more

The Landscape of Alterations from 1407 Ultra-Rare Sarcomas from the AACR GENIE Database: Clinical Implications

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0876

Top 35%

0.561DataRank

Top 35%8 citations

Justin T. Moyers, Mohamed A. Gouda, Anthony P. Conley, Alexander J. Lazar, Vivek Subbiah +1 more

Current and future targeted alpha particle therapies for osteosarcoma: Radium-223, actinium-225, and thorium-227

Frontiers in Medicine(2022)10.3389/fmed.2022.1030094

N/A

0.506DataRank · unranked

10 citations

Vivek Subbiah, Matteo Trucco, Peter M. Anderson

Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancer

BMJ Oncology(2024)10.1136/bmjonc-2023-000133

N/A

0.473DataRank · unranked

13 citations

Genevieve Hartley, Coline Couillault, Ying Yuan, Heather Lin, Courtney Nicholas +18 more

Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study

European Journal of Cancer(2022)10.1016/j.ejca.2022.06.024

N/A

0.449DataRank · unranked

19 citations

Daniel Castellano, Jerome Alexandre, Sant P. Chawla, Cristian Fernández, Carmen Kahatt +9 more

A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors

The Oncologist(2023)10.1093/oncolo/oyad158

N/A

0.438DataRank · unranked

10 citations

Apostolia M. Tsimberidou, Xueyao Fu, Siqing Fu, Vivek Subbiah, Anil K. Sood +7 more

Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study

ESMO Open(2022)10.1016/j.esmoop.2022.100571

N/A

0.427DataRank · unranked

11 citations

Barbara Pistilli, Irene Braña, Geoffrey I. Shapiro, José Trigo, Víctor Moreno +13 more

Phase I study of sapanisertib (CB‐228/TAK‐228/MLN0128) in combination with ziv‐aflibercept in patients with advanced solid tumors

Cancer Medicine(2024)10.1002/cam4.6877

N/A

0.418DataRank · unranked

8 citations

Bettzy Stephen, Siqing Fu, Daniel D. Karp, Vivek Subbiah, Jordi Rodon Ahnert +8 more

Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial

Scientific Reports(2022)10.1038/s41598-022-16588-3

N/A

0.375DataRank · unranked

4 citations

David S. Hong, Christine B. Peterson, Bettzy Stephen, Ecaterina E. Dumbrava, Shubbam Pant +18 more

Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study

Cancers(2022)10.3390/cancers14174334

N/A

0.269DataRank · unranked

5 citations

Cassandra Hennessy, Alicia Beeghly, Benjamin French, Dimpy P. Shah, Sarah Croessmann +42 more

Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I study

ESMO Open(2023)10.1016/j.esmoop.2023.101609

N/A

0.256DataRank · unranked

3 citations

X. Wang, Najat C. Daw, C.E. Herzog, Ishwaria M. Subbiah, Wafik Zaky +10 more

International Multicenter Study Comparing Cancer to Non-Cancer Patients with COVID-19: Impact of Risk Factors and Treatment Modalities on Survivorship

medRxiv(2022)10.1101/2022.08.25.22279181

Top 62%

0.234DataRank

Top 62%2 citations

Ray Hachem, Masayuki Nigo, Tarcila Santos Datoguia, Hiba Dagher, Ying Jiang +47 more

Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial

Journal of Immunotherapy and Precision Oncology(2025)10.36401/jipo-24-17

N/A

0.217DataRank · unranked

3 citations

Mohamed A. Gouda, Matthew J. Reilley, Amadeo B. Biter, JoAnn Lim, Stacie A. Bean +15 more

A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma

Cancer Medicine(2025)10.1002/cam4.70280

N/A

0.212DataRank · unranked

3 citations

Mohamed A. Gouda, Denái R. Milton, Hassan Ahmed Momin, Bülent Yılmaz, Bettzy Stephen +16 more

Pembrolizumab in Patients with Advanced Miscellaneous Rare Cancers: Results from a Phase 2 Basket Trial

Journal of Immunotherapy and Precision Oncology(2025)10.36401/jipo-24-27

N/A

0.179DataRank · unranked

2 citations

Camila Bragança Xavier, Bettzy Stephen, Jeffrey How, Justin T. Moyers, Vivek Subbiah +3 more

Demographics, outcomes, and risk factors for patients (Pts) with sarcoma and COVID-19: A multi-institutional cohort analysis.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.11523

Top 71%

0.140DataRank

Top 71%1 citations

Matthew Ingham, Corrie Painter, Rashmi Chugh, Jonathan C. Trent, Vivek Subbiah +15 more

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors

Molecular Cancer Therapeutics(2022)10.1158/1535-7163.mct-21-0950

N/A

0DataRank · unranked

39 citations

Arjun K. Menta, Neha K. Reddy, Aakash Desai, Jason Roszik, Vivek Subbiah +1 more

Temporal Trends in Outcomes in Patients With Adrenocortical Carcinoma: A Multidisciplinary Referral-center Experience

The Journal of Clinical Endocrinology & Metabolism(2022)10.1210/clinem/dgac046

N/A

0DataRank · unranked

32 citations

Jeena Varghese, Stephen K. Gruschkus, Camilo Jiménez, Steven G. Waguespack, Sara Bedrose +15 more

Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences

Scientific Reports(2022)10.1038/s41598-022-12669-5

N/A

0DataRank · unranked

24 citations

Funda Meric‐Bernstam, David S. Hong, Filip Jankú, Aung Naing, Sarina A. Piha‐Paul +13 more

Impact of tissue-agnostic approvals for patients with gastrointestinal malignancies

Trends in cancer(2022)10.1016/j.trecan.2022.11.003

N/A

0DataRank · unranked

21 citations

Vivek Subbiah, Deepak Bhamidipati

Think Globally, Act Locally: Globalizing Precision Oncology

Cancer Discovery(2022)10.1158/2159-8290.cd-22-0024

N/A

0DataRank · unranked

13 citations

Vivek Subbiah, Justin T. Moyers

Rationalizing rules for immunotherapy combination trials: About time for precision immunotherapy

Cancer(2022)10.1002/cncr.34514

N/A

0DataRank · unranked

9 citations

Vivek Subbiah, Aakash Desai

Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2509

N/A

0DataRank · unranked

9 citations

Roberto Carmagnani Pestana, Jason Roszik, David S. Hong, Aung Naing, Siqing Fu +18 more

Precision oncology for biliary tract tumors: it’s written in blood!

Annals of Oncology(2022)10.1016/j.annonc.2022.09.157

N/A

0DataRank · unranked

7 citations

Vivek Subbiah, Mohamed A. Gouda

Targeting Ferroptosis Vulnerability in Synovial Sarcoma: Is It All About ME1?

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-1257

N/A

0DataRank · unranked

5 citations

Boyi Gan, Vivek Subbiah

Targeting Oxidative Phosphorylation with a Mitochondrial Complex I Inhibitor is limited by Mechanism-based Toxicity

Research Square(2022)10.21203/rs.3.rs-1506700/v1

N/A

0DataRank · unranked

5 citations

Timothy A. Yap, Naval Daver, Mikhila Mahendra, Jixiang Zhang, Carlos Kamiya-Matsuoka +43 more

Interim phase 1 results for SQ3370 in advanced solid tumors.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3085

N/A

0DataRank · unranked

4 citations

Kathleen Batty, Maša Alečković, Vivek A. Bhadri, Nam Q. Bui, Alexander Guminski +10 more

Clinical activity of MAPK targeted therapies in patients with non-V600 BRAF mutant tumors

medRxiv(2022)10.1101/2022.02.17.22271120

N/A

0DataRank · unranked

1 citations

Yifan Wang, Rouhi Fazelzad, Benny Johnson, Caroline A. Nebhan, Ibiayi Dagogo‐Jack +24 more

Exportin(g) precision oncology beyond genomics with XPO1 inhibition

(2022)10.1016/j.medj.2022.10.005

N/A

0DataRank · unranked

0 citations

Vivek Subbiah, Mohamed A. Gouda

The next generation of evidence-based medicine

Nature Medicine(2023)10.1038/s41591-022-02160-z

N/A

0DataRank · unranked

537 citations

Vivek Subbiah

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy

ESMO Open(2023)10.1016/j.esmoop.2023.100788

N/A

0DataRank · unranked

103 citations

Vivek Subbiah, Mohamed A. Gouda

Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E–Positive Adult and Pediatric Solid Tumors

American Society of Clinical Oncology Educational Book(2023)10.1200/edbk_404770

N/A

0DataRank · unranked

93 citations

Vivek Subbiah, Mohamed A. Gouda

HER2-low expression in patients with advanced or metastatic solid tumors

Annals of Oncology(2023)10.1016/j.annonc.2023.08.005

N/A

0DataRank · unranked

72 citations

Cara Haymaker, Gabriela Raso, Serena Masciari, Lei Wang, Heather Lin +20 more

The abscopal effect in patients with cancer receiving immunotherapy

Med(2023)10.1016/j.medj.2023.02.003

N/A

0DataRank · unranked

68 citations

Jacob J. Adashek, Steven H. Lin, Vivek Subbiah, Blessie Elizabeth Nelson

Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer: Genomics Is the Diagnosis

Journal of Clinical Oncology(2023)10.1200/jco.22.02833

N/A

0DataRank · unranked

62 citations

Razelle Kurzrock, Vivek Subbiah

Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0090

N/A

0DataRank · unranked

60 citations

Blessie Elizabeth Nelson, Lars Buschhorn, Adam Wahida, Vivek Subbiah, Mohamed A. Gouda

RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives

Pharmacology & Therapeutics(2023)10.1016/j.pharmthera.2023.108344

N/A

0DataRank · unranked

48 citations

Ernesto G. Miranda-Morales, Petra den Hollander, Alex Friedlaender, Herman O. Sintim, Jie Wu +3 more

N-of-1 Trials in Cancer Drug Development

Cancer Discovery(2023)10.1158/2159-8290.cd-22-1377

N/A

0DataRank · unranked

44 citations

Lars Buschhorn, Andreas Schneeweiß, Adam Wahida, Vivek Subbiah, Mohamed A. Gouda

BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study

npj Precision Oncology(2023)10.1038/s41698-022-00341-0

N/A

0DataRank · unranked

22 citations

Jason Roszik, Filip Jankú, David S. Hong, Shumei Kato, Aung Naing +11 more

Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3629

N/A

0DataRank · unranked

21 citations

Justin T. Moyers, Jason Roszik, Shiraj Sen, David S. Hong, Aung Naing +29 more

Predicting the Abscopal Effect: Associated Tumor Histologic Subtypes and Biomarkers

Molecular Cancer Therapeutics(2023)10.1158/1535-7163.mct-22-0516

N/A

0DataRank · unranked

20 citations

Jacob J. Adashek, Aakash Akshay Sheth, Vivek Subbiah, Blessie Elizabeth Nelson

Precision oncology with selective RET inhibitor selpercatinib in RET -rearranged cancers

Therapeutic Advances in Medical Oncology(2023)10.1177/17588359231177015

N/A

0DataRank · unranked

20 citations

Vivek Subbiah, Mohamed A. Gouda

Selpercatinib and Pralsetinib Induced Chylous Ascites in RET-Rearranged Lung Adenocarcinoma: A Case Series

Clinical Lung Cancer(2023)10.1016/j.cllc.2023.08.006

N/A

0DataRank · unranked

15 citations

Joshua Wang, N Gallego, Isa Mambetsariev, Pauline Kim, Razmig Babikian +5 more

Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma

npj Precision Oncology(2023)10.1038/s41698-023-00398-5

N/A

0DataRank · unranked

11 citations

Neha K. Reddy, Jason T. Huse, Behrang Amini, Mirella Nardo, Mohamed A. Gouda +3 more

Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1703

N/A

0DataRank · unranked

10 citations

Richard K. Yang, Alexander J. Lazar, Shalin S. Patel, Valerae O. Lewis, Jason Roszik +13 more

Rare disease research powered by empowered patients: solving the zebra puzzle through social media

Cancer(2023)10.1002/cncr.34765

N/A

0DataRank · unranked

9 citations

Vivek Subbiah, Gilberto Morgan

Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies

npj Precision Oncology(2023)10.1038/s41698-023-00369-w

N/A

0DataRank · unranked

7 citations

Roman Groisberg, Ralph Zinner, Andrew W. Hahn, Aung Naing, Shizhen Zhang +16 more

Weight gain in patients with RET aberrant cancers treated with brain penetrant RET selective inhibitors

Annals of Oncology(2023)10.1016/j.annonc.2023.07.002

N/A

0DataRank · unranked

7 citations

Mimi I. Hu, Maria E. Cabanillas, Jie Wu, Funda Meric‐Bernstam, Vivek Subbiah +1 more

TRKing sarcomas for precision medicine: Seek, and ye shall find!

Cancer(2023)10.1002/cncr.34941

N/A

0DataRank · unranked

4 citations

Vivek Subbiah, Justin T. Moyers

Direct-to-Patient Clinical Trials: One Small Step or a Giant Leap?

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0746

N/A

0DataRank · unranked

3 citations

Vivek Subbiah, Aakash Desai

RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion–Positive Breast Cancer and Beyond

Cancer Research(2023)10.1158/0008-5472.can-23-1021

N/A

0DataRank · unranked

3 citations

Vivek Subbiah, Jie Wu

Sodium fluoride (Na18F) PET Response Criteria in Solid Tumors (NAFCIST): a framework for response assessment in bone tumors

ESMO Open(2023)10.1016/j.esmoop.2023.101575

N/A

0DataRank · unranked

2 citations

Mohamed A. Gouda, Lars Buschhorn, Adam Wahida, Homer A. Macapinlac, Peter M. Anderson +2 more

Multi-disciplinary management of recurrent gastrointestinal stromal tumor harboring KIT exon 11 mutation with the switch-control kinase inhibitor ripretinib and surgery`

Oncoscience(2023)10.18632/oncoscience.586

N/A

0DataRank · unranked

2 citations

Filip Jankú, Neeta Somaiah, Kelly K. Hunt, Sireesha Yedururi, Vivek Subbiah +1 more

Translating immuno-onco-microbiome-based therapeutics: precision bugs for immune checkpoint drugs!

Annals of Oncology(2023)10.1016/j.annonc.2023.03.002

N/A

0DataRank · unranked

2 citations

Shubham Pant, Vivek Subbiah

Activity of pazopanib in EWSR1-NFATC2 translocation-associated bone sarcoma

Oncoscience(2023)10.18632/oncoscience.587

N/A

0DataRank · unranked

2 citations

Maria A. Zarzour, Ara A. Vaporciyan, Kalevi Kairemo, Hubert H. Chuang, Vivek Subbiah +1 more

Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer

Journal of Immunotherapy and Precision Oncology(2023)10.36401/jipo-22-23

N/A

0DataRank · unranked

1 citations

Heather Lin, Siqing Fu, Amadeo B. Biter, Ecaterina E. Dumbrava, Daniel D. Karp +15 more

Lefitolimod (TLR agonist) and ipilimumab in patients with advanced solid tumors: A phase I trial.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.2564

N/A

0DataRank · unranked

4 citations

Matthew J. Reilley, Amadeo B. Biter, JoAnn Lim, Stacie A. Bean, Ly M. Nguyen +14 more

Data from Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

(2023)10.1158/1078-0432.c.6530655.v1

N/A

0DataRank · unranked

0 citations

Justin F. Gainor, Geoffrey R. Oxnard, Daniel S.W. Tan, Dwight H. Owen, Byoung Chul Cho +16 more

Supplementary Table S2 from Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

(2023)10.1158/1078-0432.22481301

Top 100%

0DataRank

Top 100%0 citations

Justin F. Gainor, Geoffrey R. Oxnard, Daniel S.W. Tan, Dwight H. Owen, Byoung Chul Cho +16 more

Data from Phase I Study of P-cadherin–targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors

(2023)10.1158/1078-0432.c.6529733

N/A

0DataRank · unranked

0 citations

William D. Erwin, Osama Mawlawi, Asa McCoy, David Wages, Catherine Wheeler +23 more

Data from Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)

(2023)10.1158/1078-0432.c.6532743

Top 100%

0DataRank

Top 100%0 citations

Roberto Carmagnani Pestana, Jason Roszik, David S. Hong, Aung Naing, Siqing Fu +18 more

Data from Phase I Study of P-cadherin–targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors

(2023)10.1158/1078-0432.c.6529733.v1

N/A

0DataRank · unranked

0 citations

William D. Erwin, Osama Mawlawi, Asa McCoy, David Wages, Catherine Wheeler +23 more

Data from Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)

(2023)10.1158/1078-0432.c.6532743.v1

Top 100%

0DataRank

Top 100%0 citations

Roberto Carmagnani Pestana, Jason Roszik, David S. Hong, Aung Naing, Siqing Fu +18 more

Data from Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors

(2023)10.1158/1535-7163.c.6543276.v1

Top 100%

0DataRank

Top 100%0 citations

Arjun K. Menta, Neha K. Reddy, Aakash Desai, Jason Roszik, Vivek Subbiah +1 more

Data from Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors

(2023)10.1158/1535-7163.c.6543276

Top 100%

0DataRank

Top 100%0 citations

Arjun K. Menta, Neha K. Reddy, Aakash Desai, Jason Roszik, Vivek Subbiah +1 more

Baseline symptom, health status, and health utilities in patients in early-phase clinical trials combining immune checkpoint blockade with other anticancer therapies.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.12117

N/A

0DataRank · unranked

0 citations

Sarina A. Piha‐Paul, Siqing Fu, Jordi Rodon Ahnert, Timothy A. Yap, Vivek Subbiah +10 more

Data from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations

(2023)10.1158/2159-8290.c.6749764.v1

N/A

0DataRank · unranked

0 citations

Vaibhav Sahai, Dejan Maglic, Kamil Bruderek, B. Barry Touré, Songping Zhao +26 more

Data from Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

(2023)10.1158/1078-0432.c.6727617.v2

N/A

0DataRank · unranked

0 citations

Sant P. Chawla, Anthony P. Conley, Breelyn A. Wilky, Anthony W. Tolcher, Nehal J. Lakhani +14 more

Disparities in dosing, drug reduction, and drug discontinuation among US FDA approved tyrosine kinase inhibitors

F1000Research(2023)10.12688/f1000research.124601.1

N/A

0DataRank · unranked

0 citations

Niamh Coleman, Clark R. Andersen, Ying Yuan, Vivek Subbiah, Neha K. Reddy

Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer

npj Precision Oncology(2024)10.1038/s41698-024-00563-4

N/A

0DataRank · unranked

25 citations

Mohamed A. Gouda, J. Bryan Iorgulescu, Ramona Dadu, Keyur Patel, Steven I. Sherman +8 more

Precision oncology across the ages: Impact on children, adolescents, and young adults

Cancer Cell(2024)10.1016/j.ccell.2024.08.010

N/A

0DataRank · unranked

10 citations

Razelle Kurzrock, Vivek Subbiah

RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study

Molecular Cancer(2024)10.1186/s12943-024-01982-4

N/A

0DataRank · unranked

2 citations

Jason Roszik, Jibran Ahmed, Carmelia Maria Noia Barretto, Mirella Nardo, Erick Campbell +9 more

Molecular Tumor Boards: A Consensus Statement From the International Association for the Study of Lung Cancer

Journal of Thoracic Oncology(2025)10.1016/j.jtho.2025.07.009

N/A

0DataRank · unranked

5 citations

Julia Rotow, Maria E. Arcila, M. Hatton, Lynette M. Sholl, Christian Rolfo +35 more

Selpercatinib mitigates cancer cachexia independent of anti-tumor activity in the HT1080 tumor model

Cancer Letters(2025)10.1016/j.canlet.2025.217444

N/A

0DataRank · unranked

3 citations

Mohamed A. Gouda, Shriya Pandey, Neeraj Chauhan, Tao Shen, Xueqing Hu +5 more

A first-in-human, Phase 1/2a, open-label study of SQ3370, a first-in-class doxorubicin-based click chemistry therapeutic, in patients with advanced solid tumors

medRxiv(2025)10.1101/2025.06.02.25328445

N/A

0DataRank · unranked

2 citations

Esteban Abella, Stefan Wieland, Thu‐Ha Nguyen, Sangeetha Srinivasan, M. Alečković +10 more

Data from Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

(2023)10.1158/1078-0432.c.6727617.v1

N/A

0DataRank · unranked

0 citations

Sant P. Chawla, Anthony P. Conley, Breelyn A. Wilky, Anthony W. Tolcher, Nehal J. Lakhani +14 more

The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians

Annals of Oncology(2020)10.1016/j.annonc.2020.07.002

N/A

0DataRank · unranked

253 citations

David B. Solit, Timothy A. Chan, Razelle Kurzrock, Vivek Subbiah

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations

Annals of Oncology(2020)10.1016/j.annonc.2020.10.599

N/A

0DataRank · unranked

249 citations

Tao Shen, S. Terzyan, X. Liu, Xueqing Hu, Khadijah Patel +8 more

Pan-Cancer Efficacy of Vemurafenib in BRAF V600-Mutant Non-Melanoma Cancers

Cancer Discovery(2020)10.1158/2159-8290.cd-19-1265

N/A

0DataRank · unranked

126 citations

Igor Puzanov, Jean‐Yves Blay, Ian Chau, A. Craig Lockhart, Noopur Raje +11 more

Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies

Scientific Reports(2020)10.1038/s41598-020-58366-z

N/A

0DataRank · unranked

20 citations

Filip Jankú, Sarina A. Piha‐Paul, Kenneth R. Hess, Russell R. Broaddus, Lidong Liu +11 more

Trial Sponsorship and Time to Reporting for Phase 3 Randomized Cancer Clinical Trials

Cancers(2020)10.3390/cancers12092636

N/A

0DataRank · unranked

6 citations

Clifton D. Fuller, Vivek Verma, W. Ian P. Mainwaring, Andres F. Espinoza, Austin B. Miller +10 more

Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes

Molecular Cancer Research(2020)10.1158/1541-7786.mcr-20-0751

N/A

0DataRank · unranked

11 citations

Andrew W. Hahn, Pavlos Msaouel, Alexander Andreev-Drakhlin, Funda Meric‐Bernstam, Aung Naing +17 more

Managing Cancer Care during the COVID-19 Pandemic and Beyond

Trends in cancer(2020)10.1016/j.trecan.2020.04.005

N/A

0DataRank · unranked

36 citations

Vivek Subbiah, Omar Alhalabi

IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers

Cancers(2020)10.3390/cancers12071768

N/A

0DataRank · unranked

36 citations

Ajaykumar C. Morani, Najat C. Daw, Salah-Eddine Lamhamedi-Cherradi, Vivek Subbiah, Brian A. Menegaz +22 more

Phase I Study of P-cadherin–targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-0037

N/A

0DataRank · unranked

30 citations

William D. Erwin, Osama Mawlawi, Asa McCoy, David Wages, Catherine Wheeler +23 more

Precision therapy for RET-altered cancers with RET inhibitors

Trends in cancer(2021)10.1016/j.trecan.2021.07.003

N/A

0DataRank · unranked

174 citations

Vamsidhar Velcheti, Blaine H. M. Mooers, Jie Wu, Vivek Subbiah, Kyaw Zin Thein

COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials

Nature Reviews Clinical Oncology(2021)10.1038/s41571-021-00487-z

N/A

0DataRank · unranked

140 citations

Justin F. Gainor, Aparna Hegde, Alison M. Schram, Giuseppe Curigliano, Sumanta K. Pal +19 more

Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2020-001752

N/A

0DataRank · unranked

54 citations

Christian Rolfo, Murat Ak, Mira Ayoub, Sara Ahmed, Nabil Elshafeey +13 more

Current update on gallbladder carcinoma

Abdominal Radiology(2021)10.1007/s00261-020-02871-2

N/A

0DataRank · unranked

45 citations

Avinash Kambadakone, Paul Nikolaidis, Vivek Subbiah, Ishwaria M. Subbiah, Catherine Devine +1 more

Hallmarks of RET and Co-occuring Genomic Alterations inRET-aberrant Cancers

Molecular Cancer Therapeutics(2021)10.1158/1535-7163.mct-21-0329

N/A

0DataRank · unranked

44 citations

Aakash Desai, Alexander Andreev-Drakhlin, Jason Roszik, Gilbert J. Cote, Vivek Subbiah +1 more

Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies

British Journal of Cancer(2021)10.1038/s41416-020-01230-8

N/A

0DataRank · unranked

43 citations

Filip Jankú, Vivek Subbiah, John Stewart, Sapna P. Patel, Ahmed O. Kaseb +10 more

PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers

ESMO Open(2021)10.1016/j.esmoop.2021.100230

N/A

0DataRank · unranked

41 citations

S. Greg Call, Helen J. Huang, A.L. Stuckett, Kiran Madwani, Abha Adat +16 more

The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib

npj Precision Oncology(2021)10.1038/s41698-021-00188-x

N/A

0DataRank · unranked

49 citations

Xueqing Hu, Xuan Liu, Vivek Subbiah, Blaine H. M. Mooers, Jie Wu +1 more

Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study

npj Precision Oncology(2021)10.1038/s41698-021-00159-2

N/A

0DataRank · unranked

27 citations

David S. Hong, Siqing Fu, Daniel D. Karp, Sarina A. Piha‐Paul, Merrill S. Kies +16 more

Food and Drug Administration approvals in phase 3 Cancer clinical trials

BMC Cancer(2021)10.1186/s12885-021-08457-5

N/A

0DataRank · unranked

27 citations

Ramez Kouzy, Marc Ghabach, Roshal R. Patel, Dario Pasalic, Elie Ghossain +9 more

Impact of tissue-agnostic approvals for patients with sarcoma

Trends in cancer(2021)10.1016/j.trecan.2021.11.007

N/A

0DataRank · unranked

24 citations

Juliana Rodrigues Beal, Amanda Parkes, Nelson Hamerschlak, Vivek Subbiah, Roberto Carmagnani Pestana

Discovery of targeted expression data for novel antibody-based and chimeric antigen receptor-based therapeutics in soft tissue sarcomas using RNA-sequencing: clinical implications

Current Problems in Cancer(2021)10.1016/j.currproblcancer.2021.100794

N/A

0DataRank · unranked

10 citations

Jason Roszik, Roman Groisberg, Shiraj Sen, Brian A. Van Tine, Anthony P. Conley +2 more

Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study

ESMO Open(2021)10.1016/j.esmoop.2021.100079

N/A

0DataRank · unranked

13 citations

Ruth Sacks, Ishwaria M. Subbiah, Neele Drobnitzky, Sarina A. Piha‐Paul, David S. Hong +15 more

Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma

ESMO Open(2021)10.1016/j.esmoop.2021.100172

N/A

0DataRank · unranked

12 citations

Sudhakiranmayi Kuravi, Siddhartha Ganguly, Danny R. Welch, Carolyn J. Vivian, Muhammad Umair Mushtaq +11 more

Combination Therapies for Precision Oncology: The Ultimate Whack-A-Mole Game

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0254

N/A

0DataRank · unranked

8 citations

Vivek Subbiah, Roman Groisberg

A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies

OncoTargets and Therapy(2021)10.2147/ott.s291801

N/A

0DataRank · unranked

3 citations

Ecaterina E. Dumbrava, Binoj C. Nair, Wendy Xiong, Xu Li, Rosa Mostorino +12 more

Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials

Clinical Genitourinary Cancer(2021)10.1016/j.clgc.2021.07.004

N/A

0DataRank · unranked

2 citations

Andrew W. Hahn, Pavlos Msaouel, Funda Meric‐Bernstam, Nathaniel R. Wilson, Aung Naing +18 more

Tissue is Still the Issue for Precision Oncology: A Novel Web-Based Platform for Lesion Selection and Biopsy Specimen Acquisition

Journal of Immunotherapy and Precision Oncology(2021)10.36401/jipo-21-x5

N/A

0DataRank · unranked

1 citations

Vivek Subbiah

Author response to Cunha et al

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-003299

N/A

0DataRank · unranked

5 citations

Christian Rolfo, Murat Ak, Mira Ayoub, Sara Ahmed, Nabil Elshafeey +13 more

Advances in cancer research dissemination through the pandemic and beyond

Annals of Oncology(2021)10.1016/j.annonc.2021.02.013

N/A

0DataRank · unranked

0 citations

Ishwaria M. Subbiah, Vivek Subbiah, Aakash Desai

Patients with advanced solid cancers treated with ERK inhibitors exhibit pseudo-progession in lymphatic nodes.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.3138

N/A

0DataRank · unranked

0 citations

Daniel D. Karp, Abha Adat, Timothy A. Yap, Siqing Fu, Jordi Rodon Ahnert +12 more

Unravelling the underpinnings of hyperprogression and immunotherapy: back to the bench

Oncotarget(2021)10.18632/oncotarget.28098

N/A

0DataRank · unranked

0 citations

Razelle Kurzrock, Vivek Subbiah

Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

Annals of Oncology(2022)10.1016/j.annonc.2021.12.014

N/A

0DataRank · unranked

349 citations

Robert J. Kreitman, Zev A. Wainberg, Y. Choi, Jan H.M. Schellens, Jean‐Charles Soria +9 more

Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

Annals of Oncology(2022)10.1016/j.annonc.2022.08.002

N/A

0DataRank · unranked

181 citations

Giuseppe Curigliano, Michael Thomas, Vivek Subbiah, Christina S. Baik, Daniel S.W. Tan +21 more

Vivek Subbiah

Indexed papers

Top data-sharing exemplar

Papers